The recent election results have significant implications for healthcare policy in the United States. This includes potential changes in interoperability, data sharing regulations, and the impact on pharmaceutical companies and Medicare Advantage insurers.
The new administration and Congress will influence policies surrounding artificial intelligence (AI) in healthcare and cybersecurity. The Biden administration has established frameworks like the Trusted Exchange Framework and Common Agreement (TEFCA) and the Health Data, Technology, and Interoperability (HTI) rules, which may be challenging to reverse. It is important to understand upcoming regulatory changes, especially regarding AI reporting requirements.
The healthcare sector is anticipating potential regulatory benefits under the Trump administration, particularly for pharmaceutical companies and Medicare Advantage insurers. Medicare Advantage insurers saw an increase in stocks following the election, reflecting optimism about a more favorable regulatory environment. The Pharmaceutical Research and Manufacturers of America (PhRMA) expressed eagerness to collaborate with Trump and emphasized the need for innovation in the biopharmaceutical industry. They criticized the Biden administration's efforts to lower drug costs, arguing that it stifles innovation and affordability.
HIMSS is advocating for the continuation of telehealth and remote patient monitoring services, which were expanded during the COVID-19 pandemic. Congress must act before the end of the year to maintain these flexibilities.
The potential rollback of the Affordable Care Act (ACA) is a concern for healthcare advocates, as it could threaten healthcare affordability and consumer protections.
The pharmaceutical industry is expecting a shift in dynamics with Trump's return to the White House. They are optimistic about fostering an environment conducive to innovation while ensuring patients benefit from lower costs. Patient advocacy groups are monitoring the election's aftermath, particularly regarding drug pricing policies. They urge the new administration to uphold commitments made by Trump, such as allowing Medicare to negotiate lower prices and implementing the "Most Favored Nation" model.
Reproductive rights advocates are concerned about potential setbacks in access to reproductive healthcare. They fear a rollback of reproductive freedoms and emphasize the need to protect these rights.
The interplay between regulatory changes, industry dynamics, and patient advocacy will shape the future of healthcare in the United States.